Cocrystal Pharma Inc

-0.03 (-2.78%)
Other Pre-Announcement

Cocrystal Pharma Reports Q2 Loss Per Share $0.04

Published: 08/16/2021 12:33 GMT
Cocrystal Pharma Inc (COCP) - Cocrystal Pharma Reports Second Quarter 2021 Financial Results and Provides Antiviral Program and Milestone Updates.
Q2 Loss per Share $ Reported Cash and Cash Equivalents of $67.1 Million As of June 30, 2021.
$67 Million in Cash at Quarter-end is Expected to Fund Current Operations Beyond 2024.
Two Ind-enabling Studies in Covid-19 Program Expected to Begin in First Half of 2022 Prior to Phase 1 Clinical Trials.